Semaglutide for heart health in schizophrenia with metabolic syndrome
Part of Hormones & metabolism, Mental health clinical trials.
This study tests whether semaglutide (a medicine used for diabetes and weight loss) can improve heart health and blood sugar in people with schizophrenia who also have metabolic syndrome. It may help lower the risk of heart problems in this group.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have schizophrenia and have been taking one of the newer antipsychotic medicines for at least 6 months.
- You also have metabolic syndrome (a group of conditions that increase heart risk, like high blood sugar, high blood pressure, and extra belly fat).
- You are older than 25 years.
- You are not taking clozapine, aripiprazole, or a combination of antipsychotics.
- You do not have any serious medical or brain conditions, and you are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a weekly injection (semaglutide) to see if it can help lower the risk of heart disease and type 2 diabetes in women who recently had gestational diabetes. The goal is to improve long-term health after pregnancy.
This trial studies whether semaglutide can improve heart and blood-vessel outcomes in people with type 1 diabetes who use an insulin pump or automated insulin delivery. It may help reduce cardiovascular risks, but you must meet several health and medication-safety requirements.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
This study tests a medication called semaglutide (a once-weekly injection) to help people with obesity lose weight. It is for adults who have already tried lifestyle changes without success.
This trial tests if semaglutide, a medicine used for diabetes and weight loss, can help people with both psoriasis and obesity. You may qualify if you have moderate to severe psoriasis, a high body weight, and are of Chinese descent.
This trial tests if semaglutide, a diabetes and weight-loss medication, can improve psoriasis symptoms and reduce inflammation. It may be an option for people with both psoriasis and overweight or obesity, with or without diabetes.
Hear when a new Metabolic Syndrome trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.